000825816 001__ 825816
000825816 005__ 20210129225434.0
000825816 0247_ $$2doi$$a10.2967/jnumed.116.180075
000825816 0247_ $$2ISSN$$a0097-9058
000825816 0247_ $$2ISSN$$a0161-5505
000825816 0247_ $$2ISSN$$a1535-5667
000825816 0247_ $$2ISSN$$a0022-3123
000825816 0247_ $$2WOS$$aWOS:000398249600019
000825816 0247_ $$2altmetric$$aaltmetric:20474187
000825816 0247_ $$2pmid$$apmid:27754904
000825816 037__ $$aFZJ-2017-00118
000825816 082__ $$a610
000825816 1001_ $$0P:(DE-HGF)0$$aUnterrainer, M.$$b0
000825816 245__ $$a18F-FET PET uptake characteristics in patients with newly diagnosed and untreated brain metastasis
000825816 260__ $$aReston, Va.$$bSNM84042$$c2017
000825816 264_1 $$2Crossref$$3online$$bSociety of Nuclear Medicine$$c2016-10-06
000825816 264_1 $$2Crossref$$3print$$bSociety of Nuclear Medicine$$c2017-04-01
000825816 264_1 $$2Crossref$$3print$$bSociety of Nuclear Medicine$$c2017-04-01
000825816 3367_ $$2DRIVER$$aarticle
000825816 3367_ $$2DataCite$$aOutput Types/Journal article
000825816 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1491570626_657
000825816 3367_ $$2BibTeX$$aARTICLE
000825816 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000825816 3367_ $$00$$2EndNote$$aJournal Article
000825816 520__ $$aIn patients with brain metastasis, PET using labeled amino acids has gained clinical importance, mainly regarding the differentiation of viable tumor tissue from treatment-related effects. However, there is still limited knowledge concerning the uptake characteristics in patients with newly diagnosed and untreated brain metastases. Hence, we evaluated the uptake characteristics in these patients using dynamic O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET. Methods: Patients with newly diagnosed brain metastases without prior local therapy and 18F-FET PET scanning were retrospectively identified in 2 centers. Static and dynamic PET parameters (maximal/mean tumor-to-brain-ratio [TBRmax/TBRmean], biologic tumor volume [BTV], and time–activity curves with minimal time to peak [TTPmin]) were evaluated and correlated with MRI parameters (maximal lesion diameter, volume of contrast enhancement) and originating primary tumor. Results: Forty-five brain metastases in 30 patients were included. Forty of 45 metastases (89%) had a TBRmax ≥ 1.6 and were classified as 18F-FET–positive (median TBRmax, 2.53 [range, 1.64–9.47]; TBRmean, 1.86 [range, 1.63–5.48]; and BTV, 3.59 mL [range, 0.04–23.98 mL], respectively). In 39 of 45 brain metastases eligible for dynamic analysis, a wide range of TTPmin was observed (median, 22.5 min; range, 4.5–47.5 min). All 18F-FET–negative metastases had a diameter of ≤ 1.0 cm, whereas metastases with a > 1.0 cm diameter all showed pathologic 18F-FET uptake, which did not correlate with lesion size. The highest variability of uptake intensity was observed within the group of melanoma metastases. Conclusion: Untreated metastases predominantly show increased 18F-FET uptake, and only a third of metastases < 1.0 cm were 18F-FET–negative, most likely because of scanner resolution and partial-volume effects. In metastases > 1.0 cm, 18F-FET uptake intensity was highly variable and independent of tumor size (even intraindividually). 18F-FET PET might provide additional information beyond the tumor extent by reflecting molecular features of a metastasis and might be a useful tool for future clinical applications, for example, response assessment. 
000825816 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000825816 588__ $$aDataset connected to CrossRef
000825816 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b1
000825816 7001_ $$0P:(DE-HGF)0$$aSuchorska, B.$$b2
000825816 7001_ $$0P:(DE-HGF)0$$aKowalew, L.-C.$$b3
000825816 7001_ $$0P:(DE-HGF)0$$aWenter, V.$$b4
000825816 7001_ $$0P:(DE-HGF)0$$aSchmid-Tannwald, C.$$b5
000825816 7001_ $$0P:(DE-HGF)0$$aNiyazi, M.$$b6
000825816 7001_ $$0P:(DE-HGF)0$$aBartenstein, P.$$b7
000825816 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.-J.$$b8
000825816 7001_ $$0P:(DE-HGF)0$$aAlbert, N. L.$$b9$$eCorresponding author
000825816 77318 $$2Crossref$$3journal-article$$a10.2967/jnumed.116.180075$$b : Society of Nuclear Medicine, 2016-10-06$$n4$$p584-589$$tJournal of Nuclear Medicine$$v58$$x0161-5505$$y2016
000825816 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.116.180075$$gp. jnumed.116.180075$$n4$$p584-589$$tJournal of nuclear medicine$$v58$$x0161-5505$$y2016
000825816 909CO $$ooai:juser.fz-juelich.de:825816$$pVDB
000825816 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b1$$kFZJ
000825816 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000825816 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000825816 9141_ $$y2017
000825816 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2013
000825816 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000825816 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000825816 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000825816 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000825816 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000825816 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000825816 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000825816 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000825816 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000825816 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000825816 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2013
000825816 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000825816 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000825816 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000825816 980__ $$ajournal
000825816 980__ $$aVDB
000825816 980__ $$aI:(DE-Juel1)INM-3-20090406
000825816 980__ $$aI:(DE-Juel1)INM-4-20090406
000825816 980__ $$aI:(DE-82)080010_20140620
000825816 980__ $$aUNRESTRICTED